Master Alliance Provisions Guide (MAPGuide)

Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement

  • Equitable Access | Ensuring continuity

5. Supply
5.10. Supply Rights
a) In case Licensees, in view of (i) problems in the Manufacturing of the Licensed Product at Licensees premises; (ii) need to expand the Manufacturing capacity to meet the demand for the Licensed Product in the Territory; or (ii) delays in the execution of the Technology Transfer Work Plan, Manufacturing Plan, Supply Plan and Regulatory Plan, notify AstraZeneca about such instances mentioned above, AstraZeneca or any third party under AstraZeneca’s responsibility may, according to demand, availability and delivery schedule by the time of the order, agree to manufacture and commercialize the Licensed Product or the IFA [API] in the Territory to Licensees, pursuant to conditions to be negotiated in good faith between the Parties which must be the subject matter of a separate agreement.